KANG STEM HOLDINGS CO., LTD Patent applications |
Patent application number | Title | Published |
20130230924 | Equine Amniotic Fluid-Derived Multipotent Stem Cells and a Method for Producing the Same - The present invention relates to equine amniotic fluid-derived multipotent stem cells (eAF-MSCs) and a preparation method thereof. More particularly, the present invention relates to equine amniotic fluid-derived multipotent stem cells which exhibit all negative immunological characteristics with respect to the human markers, CD19, CD20, CD28, CD31, CD34, CD38, CD41a, CD62L, CD62P and CD200, and exhibit all positive immunological characteristics with respect to the human markers, CD44, CD90 and CD105, and have the ability to differentiate into ectoderm, mesoderm or endoderm-derived cells. | 09-05-2013 |
20130209422 | "Pharmaceutical Composition Comprising Stem Cells Treated with NOD2 Agonist or Culture Thereof for Prevention and Treatment of Immune Disorders and Inflammatory Diseases" - The present invention relates to a pharmaceutical composition for the prevention or treatment of immune disorders and inflammatory diseases, comprising stem cells that are generated by culturing stem cells expression Nucleotide-binding Oligomerization Domain protein 2 (NOD2) with a NOD2 agonist or a culture thereof. More particularly, the present invention relates to a method for suppressing immune responses or inflammatory responses of a subject, comprising the step of administering the pharmaceutical composition, the stem cells or culture thereof to the subject, a method for preparing an immunosuppressive drug or an anti-inflammatory drug using the stem cells or culture thereof, a method for preparing PGE | 08-15-2013 |
20130089885 | CD49F PROMOTING PROLIFERATION, MULTIPOTENCY AND REPROGRAMMING OF ADULT STEM CELLS THROUGH PI3K/AKT/GSK3 PATHWAY - The present invention relates to a method for obtaining adult stem cells, which have a surface antigen of CD49f, excellent formation of spheres due to sphere formation and high expression of OCT4 and SOX2, from a cell source including stem cells, and a cell therapeutic agent containing adult stem cells obtained by the method or cells differentiated therefrom as an active ingredient. | 04-11-2013 |